Group 1: Liquidity and Performance of Sci-Tech Pharmaceutical Index ETF - The Sci-Tech Pharmaceutical Index ETF had a turnover rate of 16.48% during the trading session, with a transaction volume of 37.98 million yuan, indicating active market trading [2] - Over the past week, the average daily transaction volume of the ETF reached 48.92 million yuan, ranking first among comparable funds [2] - In the past year, the ETF's scale increased by 154 million yuan, achieving significant growth and ranking first in new scale among comparable funds [2] - The ETF's shares grew by 130 million units in the past year, also ranking first in new shares among comparable funds [2] - As of June 10, the net value of the ETF increased by 25.51% over the past year [2] - The highest monthly return since inception was 23.29%, with the longest consecutive monthly gains being 4 months and a maximum increase of 21.76% [2] - The average monthly return during the rising months was 8.18%, with a historical one-year profit probability of 69.81% [2] Group 2: Market Trends and Investment Opportunities - The Central Committee of the Communist Party of China and the State Council issued opinions to improve the basic medical insurance drug catalog adjustment mechanism and to develop a commercial health insurance innovative drug catalog [3] - A report from Dongwu Securities indicated that there were 73 oral presentations from China at the 2025 ASCO, marking a historical high, with 89 out of 184 ADC pipeline studies coming from China, accounting for approximately 48.4% of the total [3] - The agency believes that the competitiveness of domestic innovative drugs in the global market is continuously improving, and international investors' confidence in Chinese innovative drug companies is increasing [3] - Domestic innovative drugs are transitioning from "catching up" to "leading," presenting significant investment opportunities [3] - Investors without stock accounts can access the Sci-Tech Biopharmaceutical ETF linked fund (021061) to capitalize on opportunities in the Sci-Tech Board biopharmaceutical sector [3]

证券代码：688091 证券简称：上海谊众 公告编号：2025-026 上海谊众药业股份有限公司 关于变更持续督导保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海谊众药业股份有限公司（以下简称"公司"）于近日收到国金证券股份有 限公司（以下简称"国金证券"）发来的《关于变更持续督导保荐代表人的函》。 国金证券作为公司 2021 年首次公开发行股票并在科创板上市的保荐机构，担任 公司首次公开发行股票并上市项目持续督导工作的保荐代表人秦勤女士因工作 变动，不再负责公司首次公开发行股票并上市项目的持续督导工作。为保证公司 持续督导工作的正常进行，国金证券现委派徐清卉女士（简历后附）接替秦勤女 士，担任公司持续督导保荐代表人，继续履行持续督导的保荐职责。 此次变更后，公司首次公开发行股票并上市项目持续督导保荐代表人为顾兆 廷先生和徐清卉女士。 公司董事会对秦勤女士为公司首次公开发行股票并上市及持续督导期间所 做出的贡献表示衷心的感谢！ 特此公告。 上海谊众药业股份有限公司董事会 2025 年 6 月 10 日 ...

本次公司财务总监的变更不会影响公司正常运作与经营，新任财务总监汤节节女 士具备相关专业知识和履行财务总监职责所需的能力，能够胜任公司财务总监的履 职要求，其任职资格符合相关法律法规的要求。 特此公告。 上海谊众药业股份有限公司董事会 2025 年 6 月 7 日 证券代码：688091 证券简称：上海谊众 公告编号：2025-024 上海谊众药业股份有限公司 关于变更财务总监的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海谊众药业股份有限公司（以下简称"公司"）财务总监张芷源女士因工作内 容调整，不再担任财务总监职务，张芷源女士卸任后将担任公司内部审计负责人。 张芷源女士在担任公司财务总监期间，勤勉敬业、恪尽职守，公司及公司董事会对 张芷源女士所做出的贡献表示衷心的感谢。 根据《中华人民共和国公司法》和《上海谊众药业股份有限公司章程》的相关规 定，经公司总经理提名并经董事会提名委员会、审计委员会审议通过，公司于 2025 年 6 月 6 日召开了第二届董事会第十次会议，审议通过了《关于变更公司财务总监 的议案》 ...

证券代码：688091 证券简称：上海谊众 公告编号：2025-025 上海谊众药业股份有限公司关于 2025 年度"提质增效重回报"行动方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海谊众药业股份有限公司（以下简称"公司"或"上海谊众"）为提升经营 发展质量与践行"以投资者为本"的上市公司发展理念，响应上海证券交易所《关 于开展沪市公司"提质增效重回报"专项行动的倡议》，在生产经营、公司治理及 投资者交流与回报三个层面上进行了现状分析，制定了《上海谊众药业股份有限 公司 2025 年度"提质增效重回报"行动方案》（以下简称"行动方案"），旨在全 面提升公司的经营效率与质量，维护公司的投资价值，保护投资者尤其是中小投 资者的合法权益。具体措施内容如下： 一、 聚焦主业，在稳健经营中实现高质量发展 上海谊众致力于抗肿瘤创新药及相关产品的开发，拥有高分子材料、药物制剂、 生物学等背景的高科技人才，具备独立自主的药品研发能力与完整的药品生产系 统，是一家集研发、生产、销售为一体的高科技制药企业。 公司深耕抗肿瘤创 ...

上海谊众药业股份有限公司 第二届董事会第十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 上海谊众药业股份有限公司（以下简称"公司"）第二届董事会第十次会议（以 下简称"会议"）于 2025 年 6 月 6 日以现场结合通讯方式召开。会议应出席董事 6 人， 实际出席董事 6 人，符合《中华人民共和国公司法》《上海谊众药业股份有限公司章 程》的规定。会议由董事长周劲松先生召集并主持，经全体与会董事讨论和表决， 一致通过了以下决议： 二、董事会会议审议情况 本次会议经全体董事表决，形成决议如下： 1、关于变更公司财务总监的议案； 证券代码：688091 证券简称：上海谊众 公告编号：2025-023 表决情况：赞成 6 票，反对 0 票，弃权 0 票，回避 0 票。 2、关于审议《上海谊众药业股份有限公司 2025 年度"提质增效重回报"行动 方案》的议案。 表决情况：赞成 6 票，反对 0 票，弃权 0 票，回避 0 票。 特此公告。 上海谊众药业股份有限公司董事会 2025 年 6 ...

Meeting Overview - The shareholder meeting of Shanghai Yizhong Pharmaceutical Co., Ltd. was held on March 29, 2025, at the company's conference room [1]. - A total of 68 ordinary shareholders attended the meeting, holding 101,782,296 voting rights, which accounts for 49.2406% of the total voting rights of the company [1]. Voting Results - All proposed resolutions were passed during the meeting, with the voting results showing a high level of agreement among shareholders [2][3]. - For the first resolution, 101,611,261 votes (99.8319%) were in favor, with only 90,240 votes against and 80,795 abstentions [2]. - The second resolution also received 101,611,261 votes in favor (99.8319%), with similar opposition and abstention numbers [2]. - The third resolution had 101,599,561 votes in favor (99.8204%), with 101,940 votes against and 80,795 abstentions [2]. Legal Compliance - The meeting's procedures, including the convening and voting processes, were confirmed to comply with the Company Law and the company's articles of association, ensuring the legality and validity of the resolutions passed [1][3]. Legal Witness - The meeting was witnessed by lawyers Zhou Feng and Shen Guoxing, who confirmed that the meeting's procedures and results adhered to legal standards [3]. Conclusion - The board of directors of Shanghai Yizhong Pharmaceutical Co., Ltd. announced the successful completion of the shareholder meeting and the passing of all resolutions [4].

Core Viewpoint - The legal opinion letter from Shanghai Jintiancheng Law Firm confirms that the 2024 annual general meeting of Shanghai Yizhong Pharmaceutical Co., Ltd. was convened and conducted in accordance with relevant laws and regulations, ensuring the legality and validity of the meeting and its resolutions [1][5][10]. Group 1: Meeting Procedures - The notice for the 2024 annual general meeting was issued on May 29, 2025, detailing the meeting's convenor, date, time, and voting procedures [3][4]. - The meeting was held on May 29, 2025, at 14:00, combining both on-site and online voting methods [3][4]. - The meeting adhered to the procedures outlined in the Company Law and the Rules for General Meetings of Listed Companies, confirming the legality of the convening and conducting of the meeting [5][10]. Group 2: Attendance and Voting - A total of 68 shareholders and their proxies attended the meeting, representing 101,782,296 voting shares, which accounted for 49.2406% of the total shares [5][6]. - The online voting system recorded participation from 55 shareholders, representing 23,575,983 shares, or 11.4056% of the total shares [6]. - The qualifications of all attendees, including shareholders and proxies, were verified and deemed valid [6][10]. Group 3: Resolutions and Voting Results - The meeting approved the 2024 annual report and summary, with 101,611,261 votes in favor, representing 99.8319% of the valid votes [7][8]. - Other resolutions, including the independent director's work report, received similar overwhelming support, with approval rates consistently above 99% [8][9]. - The voting results were compiled from both on-site and online votes, confirming the legitimacy of the resolutions passed during the meeting [10].

上海市锦天城律师事务所 关于上海谊众药业股份有限公司 2024 年年度股东大会的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于上海谊众药业股份有限公司 2024 年年度股东大会的 法律意见书 致：上海谊众药业股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受上海谊众药业股份有限公 司（以下简称"公司"）委托，就公司召开 2024 年年度股东大会（以下简称"本次 股东大会"）的有关事宜，根据《中华人民共和国公司法》（以下简称"《公司法》"） 《上市公司股东会规则》等法律、法规、规章和其他规范性文件以及《上海谊众 药业股份有限公司章程》（以下简称"《公司章程》"）的有关规定，出具本法律 意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用原则，对本次股东大会所涉及的相关事 项进行了必要 ...

证券代码：688091 证券简称：上海谊众 公告编号：2025-022 上海谊众药业股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 68 | | --- | --- | | 普通股股东人数 | 68 | | 2、出席会议的股东所持有的表决权数量 | 101,782,296 | | 普通股股东所持有表决权数量 | 101,782,296 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 49.2406 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 49.2406 | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 （一） 股东大会召开的时间：2025 年 5 月 29 日 （二） 股东大会召开 ...

Group 1 - Huiyu Pharmaceutical's subsidiary received drug registration certificate for Carboxymethyl Sodium Injection, which is used for treating bleeding diseases in various medical fields [1] - Baihe Co., Ltd. announced a plan for a director to reduce holdings by up to 424,000 shares, representing 0.6625% of the total share capital [1] - Kingood Co., Ltd. received a notification from a global leading automaker for a wheel project, expected to start mass production in 2026 with a lifecycle of 10 years [1][2] Group 2 - Wanhua Chemical plans to repurchase shares worth between 300 million and 500 million yuan, with a maximum repurchase price of 99.36 yuan per share [2] - Warner Pharmaceutical's subsidiary received approval for Acetylcysteine raw material drug, primarily used for treating respiratory diseases [3] - ST Mingcheng plans to publicly transfer 45% equity of its subsidiary, aiming to optimize asset structure [4] Group 3 - Qixia Construction announced a plan to reduce up to 31.5 million shares, accounting for 3% of total share capital [5][6] - Zhejiang Rongtai intends to invest 20 million yuan to establish a wholly-owned subsidiary focused on intelligent robotics [7] - Yuandong Biological received drug registration for Chloral Hydrate Enema, used for sedation and seizure control in children [9] Group 4 - Jiemai Technology's subsidiary signed a strategic cooperation agreement with a solid-state battery company to produce high-safety composite conductive materials [10] - Xianju Pharmaceutical received drug registration for Progesterone Soft Capsules, used for treating functional disorders due to luteal deficiency [11] - Lanhua Kecai's subsidiary reported a temporary production halt, with the resumption date yet to be determined [13] Group 5 - Sinopharm Modern's subsidiary received drug registration for Tocilizumab Tablets, used for treating rheumatoid arthritis and other conditions [15] - Shanghai Bank announced the resignation of its vice president due to organizational adjustments [17] - Shanghai Pharmaceutical's Ephedrine Injection passed the consistency evaluation for generic drugs [19] Group 6 - Rundu Co., Ltd. received drug registration for Amlodipine and Olmesartan Tablets, aimed at treating hypertension [21] - Zhong'an Technology announced that 61 million shares held by its controlling shareholder will be auctioned [23] - Shanghai Washba plans to purchase patent assets and establish two subsidiaries focused on hydrogen energy and solid-state battery technologies [25] Group 7 - Nuo Cheng Jianhua's new drug Tafasitamab received approval for treating relapsed/refractory diffuse large B-cell lymphoma [26] - Benli Technology plans to use up to 200 million yuan of idle funds for cash management and financial investments [28] - Taiji Co., Ltd. intends to use 60 million yuan of idle funds to purchase financial products [29] Group 8 - Haishi Co. announced that its innovative drug Anreke Fen Injection received drug registration for treating postoperative pain [32] - Yulong Co. will have its stock delisted on May 27, 2025, following a decision by the Shanghai Stock Exchange [36] - Weifu High-Tech plans to establish a joint venture with Shanghai Baolong Automotive Technology [38] Group 9 - Xichang Electric Power expects a net profit reduction of approximately 5.4 million yuan due to adjustments in the time-of-use electricity pricing mechanism [39] - Alter signed a contract worth 6.8 billion yen for the development and procurement of large truck EV kits [41] - Zhonglian Heavy Industry plans to acquire controlling stakes in its financing leasing subsidiary through public bidding [42] Group 10 - Sanyou Medical's executive plans to reduce holdings by up to 1.44% of the company's shares [43] - Hangyang Co. plans to establish a subsidiary for large modular cryogenic equipment manufacturing with an estimated investment of 557 million yuan [44] - FAW Fuwi received a notification for a dashboard project from a well-known new energy brand, with total sales expected to reach 1.06 billion yuan [45]